Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Regeneron Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
February 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
January 30, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
January 24, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
January 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
January 05, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
December 11, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
December 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
December 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
December 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
December 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
November 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
November 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Regeneron Announces Investor Conference Presentation
November 15, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
November 13, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
November 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports Third Quarter 2023 Financial and Operating Results
November 02, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
November 01, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
October 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
October 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
October 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
October 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
October 20, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
AZN
REGN
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
October 15, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.